Grace Therapeutics (GRCE) Receivables - Other (2017 - 2026)
Grace Therapeutics (GRCE) posted Receivables - Other of $20000.0 for Q1 2026, little changed sequentially from $20000.0 in Q4 2025, and down 84.13% YoY from $126000.0 in Q1 2025.
Grace Therapeutics (GRCE) Receivables - Other (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Receivables - Other for 10 years, with the latest figure at $20000.0 in Q1 2026.
- Quarterly Receivables - Other fell 84.13% year-over-year to $20000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20000.0 (down 84.13% YoY) and the FY2026 annual result came in at $20000.0, down 84.13% from the prior year.
- Receivables - Other held at $20000.0 in Q1 2026 per GRCE's latest filing, from $20000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $415000.0 in Q3 2024 and troughed at $11000.0 in Q1 2022.
- A 5-year average of $76214.3 and a median of $27500.0 in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2023 and 2025: Receivables - Other jumped 372.73% in 2023, then tumbled 95.18% in 2025.
- Over 5 years, Receivables - Other stood at $11000.0 in 2022, then soared by 1390.91% to $164000.0 in 2023, then tumbled by 87.8% to $20000.0 in 2024, then changed by 0.0% to $20000.0 in 2025, then changed by 0.0% to $20000.0 in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $20000.0, $20000.0, and $20000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20,000.00 |
| Jun 30, 2026 | 20,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 126,000.00 |
| Mar 31, 2025 | 126,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Mar 31, 2024 | 35,000.00 |